Navigation Links
Orexigen(R) Therapeutics to Speak at Upcoming Conferences
Date:9/9/2009

SAN DIEGO, Sept. 9 /PRNewswire-FirstCall/ -- Orexigen((R) )Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at two upcoming investor conferences. The details are as follows:

    Morgan Stanley Global Healthcare Unplugged Conference
    Date:  September 15, 2009
    Time:  9:45am Eastern Time
    Location:  Grand Hyatt Hotel, New York
    Speaker:  Michael Narachi, President and Chief Executive Officer

    NewsMakers in the Biotech Industry Conference
    Date:  September 16, 2009
    Time:  11:30am Eastern Time
    Location:  Millennium Broadway Hotel, New York
    Speaker:  Graham Cooper, Chief Financial Officer

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave((R),) has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second product, Empatic(TM), is in the later stages of Phase 2 clinical development, with results expected in the second half of 2009. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found athttp://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics Appoints Mark Booth Chief Commercial Officer
2. Orexigen(R) Therapeutics to Speak at Canaccord Adams Global Growth Conference
3. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
4. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
5. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
6. Orexigen(R) Therapeutics to Present at Upcoming Meetings
7. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
8. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
9. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
10. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
11. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... NEW YORK , March 24, 2017 ... Composite ended the trading session at 5,817.69, down 0.07%; ... finish at 20,656.58; and the S&P 500 closed at ... session as 4 sectors closed in green, 4 sectors ... the day. This Friday, Stock-Callers.com has initiated reports coverage ...
(Date:3/23/2017)... Diego, Calif. (PRWEB) , ... March 23, 2017 , ... Lajollacooks4u is proud to announce ... 2008, it has hosted corporate cooking challenges for companies around the world, such as Illumina, ... , Part of the reason for its increasing popularity is due to its new team ...
(Date:3/23/2017)... -- GlobeImmune, Inc. today announced it has entered into a ... of its common stock to NantCell, Inc., a member ... sale of its common stock, NantCell has agreed to ... 200,000 shares, an estimated $2.0 million in value, of ... to enter into this strategic agreement with NantCell," said ...
(Date:3/23/2017)... -- NetworkNewsWire Editorial Coverage  ... Cancer remains one of the ... care systems, in terms of costs and resources. However, as ... development of innovative and efficient therapies that demonstrate higher chances ... of cancer treatments, a growing number of patients receiving immuno-oncology ...
Breaking Biology Technology:
(Date:3/20/2017)... -- PMD Healthcare announces the release of its new ... (WMS), a remote, real-time lung health monitoring and management ... a Medical Device, Digital Health, and Chronic Care Management ... solutions that empower people to improve their healthcare and ... the first ever personal spirometer, Spiro PD, which was ...
(Date:3/13/2017)... Germany , March 13, 2017 Future of security: ... ... DERMALOGs Face Matching enables to match face ... forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, ... Simple," and 23andMe , the leading personal genetics ... choices.  Zipongo can now provide customers with personalized nutrition ... goals and biometrics, but also genetic markers impacting how ... Zipongo,s personalized food decision support platform uses biometrics ...
Breaking Biology News(10 mins):